Navigation Links
Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Date:10/30/2008

CAMBRIDGE, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2008. At September 30, 2008, Idenix's cash, cash equivalents and marketable securities totaled approximately $60.1 million.

2008 Year-to-Date Business Highlights

-- Idenix completed its phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1, which demonstrated potent antiviral activity at all doses tested. Patients receiving once-daily IDX899 achieved a mean plasma viral load reduction of approximately 1.8 log10 after seven days of treatment in each of the 800 mg, 400 mg, 200 mg and 100 mg dosing cohorts (n=8 per treatment group). Patients receiving placebo (n=8) had a mean viral load increase of 0.10 log10 over the same treatment period. The safety profile of IDX899 observed during this study was comparable to placebo, with no serious adverse events reported and no pattern of adverse events or laboratory abnormalities observed on treatment. Additionally, no patients who received treatment discontinued the study.

-- Idenix also continued to advance its HCV discovery and development programs, successfully completing a first-in-man phase I study of IDX184, a nucleotide prodrug candidate, and initiating the IND-enabling preclinical studies for IDX375, a non-nucleoside polymerase inhibitor, and IDX136 and IDX316, macrocyclic protease inhibitor drug candidates.

"As we advance our HCV and HIV discovery and devel
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... A newly ... new ideas to lower the barriers to innovation in life sciences R&D. The Pistoia ... to two cash prizes of US$15,000 and a period of expert mentorship from a ...
(Date:7/1/2015)... 1, 2015  UCB, a multinational biopharmaceutical company, ... leader in designing, transforming, and running intelligent business ... recognition of their close collaboration in driving transformation ... business services (GBS) finance organization. The ... that work together effectively to embrace the innovative ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... hosting a webinar to provide advanced scientific research into new classes of Nanoscale ... and energy. Touted as 'the wonder material of the 21st Century' by ...
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome ... new insights on mechanics of fecal microbiota transplantation in C. difficile patients. , ... microbiome of patients undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium ...
Breaking Biology Technology:Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... newsletter hit a nerve as sharply as social networking has. In ... than I seem to receive on all other topics combined. (Something ... little lonely in my office.) , ,Last week, I wrote that ... , ,I said, "The value is in actively working the network ...
... campus, professors work to impart the theory and the ... for many professions, skill with information technology is key ... the School of Library and Information Studies (SLIS) at ... SLIS train students to organize and manage information. Theoretically, ...
... Corporation and EraGen Biosciences , two ... Wednesday allowing Promega to develop products using EraGens ... distribution rights for research assays. , ,Promega ... our recent SARS detection system. A market presence ...
Cached Biology Technology:Social networks: Readers respond 2Social networks: Readers respond 3Social networks: Readers respond 4Closing the IT gap 2
(Date:6/12/2015)...  Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, announced the United States ... analyze and identify participants of a video visitation ... This system can: , Identify that ... sign-on process is actually the person participating in ...
(Date:6/10/2015)... , June 10, 2015 ... Sensor Market by Technology (Ultrasound, TOF, Structured Light, ... Electronics, Entertainment, Automotive) and by Geography - Trends ... MarketsandMarkets, the market is expected to reach $3,319.71 ... 25.51% between 2015 and 2020. Browse ...
(Date:6/9/2015)... June 09, 2015 Research and Markets ... the "Gesture Recognition & Touchless Sensing Market ... Automotive, & Others), Product (Biometric & Sanitary Equipment) ... report to their offering. The ... expected to reach $ 23.55 Billion by 2020 ...
Breaking Biology News(10 mins):Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 23D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... A joke among two Texas AgriLife Research scientists ... aid fetal development in female sheep. Female sheep (ewes) ... an excellent animal model for studying the physiology of ... which is used to treat male erectile dysfunction, enhanced ...
... The fact that glaciers in the Himalayan mountains are ... to rigorously examine and quantify the causes. Lawrence Berkeley ... the impacts of the most commonly blamed culpritgreenhouse gases, ... that may be causing the melting. Menon and her ...
... This release is available in <A ... the Pontifcia Universidade Catlica do Paran and ... potential of purified and expanded CD133+ cells ... myocardial infarction by intramyocardially injecting them into ...
Cached Biology News:Study shows male erectile dysfunction drug enhances fetal growth in female sheep 2Black carbon a significant factor in melting of Himalayan glaciers 2Black carbon a significant factor in melting of Himalayan glaciers 3
Human Xg Affinity Purified Polyclonal Ab Keywords: Xg glycoprotein, hereditary hemorrhagic telangiectasia Protein Family: ...
...
20X TE buffer *RNase free*...
Sheep Serum US Origin...
Biology Products: